Adipose Derived Regenerative Cellular Therapy of Chronic Wounds

Inclusion Criteria: * Female or male patient aged ≥ 18 * With diagnosis of diabetic or other chronic wound * Grade 1 or 2 wound on the Wagner Scale * Ulcer with a surface area comprised greater than 4 cm2 included (after mechanical debridement of the ulcer) * For subjects with more than one wound that meet these criteria, all qualifying wounds may be treated * Patient's wound has been refractory to standard of care (no measureable signs of healing for at least 30 days) * Patient has adequate (\>200cc) abdominal or other subcutaneous adipose tissue accessible by syringe-based lipoharvest * Patient has activated platelet thromboplastin time (aPTT) of \< 1.6x the mean normal reference interval at the time of the lipoharvest procedure and no contraindication to lipoharvest Exclusion Criteria: * Typical Charcot's foot * Presence of osteitis (eq Br osteomyelitis) at the inclusion visit (evidenced with a radiological lesion facing the wound \[bone erosion or disappearance of the cortical bone\]) as determined by MRI * Clinical evidence of uncontrolled infection at the inclusion visit * Patient not eligible for syringe-based lipoharvest of at least 200cc of subcutaneous adipose tissue * Subjects with cancerous or pre-cancerous lesions in the area to be treated * Patient with working activity who cannot be on sick-leave during the study period * Patient suffering from a psychiatric disorder not treated * Clinical evidence of gangrene on any part of the affected foot * Patient receiving corticosteroids, NSAIDs, immunosuppressive or cytotoxic agents, all systemic agents that can affect wound repair or any treatment that might interfere with the assessment of the study treatment * Pregnant or nursing females * Patient receiving dialysis for renal insufficiency or who have severe renal dysfunction * Patient who cannot have an off-loading method * Participation in any other clinical research study that has not reached the primary efficacy endpoint or otherwise would interfere with the patient's participation in this study * Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study